Abstract: PO0875
Dysregulation of Fatty Acid Binding Protein and Their Relationship with Inflammatory Biomarkers in ESRD
Session Information
- Fluid, Electrolytes, and Clinical Events with Dialysis: Getting to the "Heart" of the Matter
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Bontekoe, Emily, Loyola University Health System, Maywood, Illinois, United States
- Bansal, Vinod K., Loyola University Health System, Maywood, Illinois, United States
- Siddiqui, Fakiha, Loyola University Health System, Maywood, Illinois, United States
- Iqbal, Omer M., Loyola University Health System, Maywood, Illinois, United States
- Fareed, Jawed, Loyola University Health System, Maywood, Illinois, United States
Background
End stage renal disease (ESRD) patients are at high risk of cardiovascular disorders and hemostatic complications. Fatty acid binding proteins (FABPs) regulate the transport of fatty acids and other lipophilic mediators such as eicosanoids and retinoids by both intracellular and extracellular mechanisms. While upregulation of FABPs have been reported in ESRD, their relationship with inflammatory biomarkers is not fully understood. Liver fatty acid binding protein (L-FABP) also known as FABP-1 is a 14kDa protein expressed in the liver. This protein is also expressed in tubular kidney cells. Kidney damage and other pathologic conditions result in the marked upregulation of this protein.
Methods
Citrated blood samples from 95 ESRD patients undergoing maintenance hemodialysis were collected prior to hemodialysis. For comparison purposes normal human plasma collected from 50 normal healthy male and female individuals were used. Plasma prepared from these patients and normal individuals was analyzed for FABP-1 and such inflammatory biomarkers as IL-6, TNFa and inflammasomes as using commercially available ELISA methods. All results were compiled and correlation analysis between FABP-1 levels and biomarkers of inflammation was carried out using GraphPad prism software.
Results
The ESRD patients showed a marked increase in FABP levels (106 ng/ml + 18ng/ml SEM) with a broad range (8 – 974 ng/ml) in comparison to normal (5.1 + 0.2ng/ml SEM) with a range of (3.4 – 9.2 ng/ml). Marked increases in IL-6, TNFa and inflammation were also noted (2 – 4 fold). FABP-1 showed varying degrees of positive correlation with inflammatory biomarkers.
Conclusion
These studies suggest that plasma levels of FABP-1 is markedly increased (up to 10 fold) in ESRD patients undergoing maintenance hemodialysis. Other biomarkers of inflammation are also upregulated and demonstrate varying degrees of correlation suggesting inter-relationship between FABP-1 and inflammatory processes. These results also suggest that impaired renal function and tubular damage contribute to the marked increase of LFABP in ESRD patients. Simultaneous measurement of LFABP with biomarkers of inflammatory responses and kidney damage may be helpful in the risk stratification and prediction of the adverse outcome in ESRD patients.
Funding
- Private Foundation Support